52 Week Range
As of on the National Stock Exchange of India ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Dr Reddy's, Cipla, Emcure, Sun Pharma And Torrent To Partner For Clinical Trial Of Molnupiravir For COVID-19
Cipla Gets Final Approval For Generic Version Of Sunovion Pharmaceuticals' Brovana
Cipla Says Roche's Antibody Cocktail (Casirivimab & Imdevimab) Now Available In India
Cipla Limited is a holding company. The Company is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered dose inhalers, dry powder inhalers, nasal sprays, nebulizers and a range of inhaled accessory devices. Cipla Global Access is a tender-based institutional business that concentrates on approximately four therapy areas: human immunodeficiency virus/acquired immuno deficiency syndrome (HIV/AIDS), malaria, multi drug-resistant tuberculosis and reproductive health. The Company offers its products for the therapeutic areas, including cardiovascular, children's health, dermatology and cosmetology, diabetes, HIV/AIDS, infectious diseases and critical care, malaria, neurosciences, oncology, ophthalmology, osteoporosis, respiratory, urology and women's health.
Biotechnology & Drugs
Yusuf K. Hamied
Non-Executive Chairman of the Board
Global Chief Executive Officer, Managing Director, Executive Director
Executive Vice Chairman of the Board
M. K. Hamied
Non-Executive Vice Chairman of the Board
Global Chief Financial Officer
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Indian drugmaker Cipla Ltd has received regulatory approval to distribute partner Moderna Inc's COVID-19 vaccine in the country, a senior government official said on Tuesday, clearing the way for the shot to be imported.
India's Cipla Ltd has been granted a new drug permission for restricted use of Moderna Inc's COVID-19 vaccine in the country, a senior government official said on Tuesday.
Indian drugmaker Cipla Ltd said on Monday it has entered into a licensing agreement with U.S. company Eli Lilly and Co to make and sell Lilly's arthritis drug baricitinib for the treatment of COVID-19 patients. (Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Rashmi...
India's Cipla Ltd has doubled production of COVID-19 medication remdesivir to help meet "unprecedented demand" as the country battles a massive second wave of infections, the drugmaker said on Tuesday.
Indian shares ended higher on Monday after scaling record peaks earlier in the session, with Burger King India soaring more than 100% in its market debut and gains in drugmaker Cipla helping boost the Nifty.
Demand for COVID-19 antiviral drug remdesivir is rising sharply in India, a top executive at drugmaker Cipla Ltd <CIPL.NS> said on Monday, even as experts remain divided over its effectiveness.
India's supply of antiviral drug remdesivir and generic equivalents is stabilising after shortages of the vital COVID-19 medicine at hospitals, according to a top executive at one of the country's big drugmakers, Cipla Ltd.
Cipla Ltd has received Indian regulatory approval to sell anti-viral drug favipiravir to treat COVID-19, the drugmaker said on Friday, as coronavirus infections in the world's third worst-hit nation show no sign of abating.
Cipla Ltd has priced its generic version of remdesivir, Cipremi, at 4,000 rupees ($53.34) per 100 mg vial, the Indian drugmaker said on Wednesday, making it among the lowest priced versions of the COVID-19 treatment available so far globally.
Indian drugmaker Cipla Ltd has priced its generic version of Remdesivir, Cipremi, at 4,000 rupees ($53.34) per 100 mg vial, according to several sources, making it among the lowest priced versions of the COVID-19 treatment available so far globally.
* CIPLA LTD SAYS COMMERCIALLY LAUNCHES CIPREMI (REMDESIVIR) ON WEDNESDAY -STATEMENT
India's Sovereign Pharma said it has dispatched the first batch of generic remdesivir for drugmaker Cipla Ltd, as the country recorded more than 22,000 new coronavirus cases on Tuesday.
Indian drugmaker Cipla Ltd will price its generic version of Gilead Sciences Inc's antiviral drug remdesivir for use in COVID-19 patients at less than 5,000 rupees ($66), the company said.
India's drug regulator has given Hetero Labs and Cipla Ltd <CIPL.NS> the green light to manufacture and market their generic version of Gilead Sciences Inc's <GILD.O> experimental COVID-19 treatment remdesivir, the Indian pharmaceutical companies said on Sunday.
* SIGNS DISTRIBUTION AGREEMENT WITH ROCHE PRODUCTS (INDIA) PVT. LTD
Indian drugmaker Zydus Cadila said on Friday it signed a non-exclusive licensing pact with Gilead Sciences Inc to manufacture and market antiviral drug remdesivir, the first treatment to show improvement in COVID-19 trials.
* CIPLA LTD -RECEIVES FINAL APPROVAL FOR GENERIC VERSION OF MIGRANAL® (DIHYDROERGOTAMINE MESYLATE NASAL SPRAY 4MG/ML) Source text for Eikon: Further company coverage:
Indian shares slipped on Monday as investors were unimpressed by the government's economic relief measures and coronavirus cases continued to rise steadily, while a boost in Reliance Industries and Cipla limited losses.
* CIPLA FILES ANDA FOR GENERIC VERSION OF GSK'S ADVAIR DISKUS Source text for Eikon: Further company coverage:
* CIPLA LTD - APPROVED RAISING OF FUNDS OF UPTO 30 BILLION RUPEES Source text for Eikon: Further company coverage:
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.